AZD2171 cancer drug molecule

AZD2171 cancer drug molecule


Rights Managed


AZD2171 cancer drug. Computer model of a molecule of the cancer drug AZD2171. This drug (trade name Recentin) is being developed by AstraZeneca. As of 2007 it is undergoing clinical trials for treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumours of the central nervous system in children. It belongs to a class of drugs known as tyrosine kinase inhibitors. These drugs bind to tyrosine kinase growth factor receptors on the cancer cell's surface, inactivating them and so stopping cell growth and proliferation. Atoms are colour-coded: carbon (yellow), hydrogen (white), nitrogen (blue), fluorine (green) and oxygen (red).

Release details

Model release not required. Property release not required.

 {{ i.shot_duration ? i.shot_duration + ' ' : '' }}{{ i.shot_uhd ? '4K ' : i.hires ? 'HD ' : '' }}{{ i.spl_number }} R{{ i.license }}

  • Add to board
  • Similar {{ mediaType(i) }}